Active · per the CBE, 19 September 2026

CESI-PREMED

BE0887903059

Rechtspersoon General partnership

Tiensevest 61 box 2, 3010 Leuven

Active for

19 year, 6 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Not on Peppol Peppol

    Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2026

CESI-PREMED from Leuven, company number BE0887903059, closed financial year 2026 with a result of € 0 after tax. For that financial year CESI-PREMED recorded revenue of € 0 and equity of € 19,124. Compared with financial year 2025, the result moved from € -515 to € 0. Around break-even. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.

What it is worth Healthy

€ 19,124

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit

€ 0

▲ still € 515 loss in 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 19,124

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2026. Retained profit grew to € 16,624.

Debts at end 2026

Bank debt

None

No bank loans on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
2023202420252026Change 2025 → 2026
Revenue € 111,497 € 112,175 € 112,832 € 0 ▼ 100%
Gross margin € 3,010 € 3,030 € -35 € 0 ▲ € 35
Profit after taxes € 2,986 € 3,002 € -515 € 0 ▲ € 515
Equity € 16,637 € 19,639 € 19,124 € 19,124
Total debts € 58,907 € 85,121 € 0 € 0
Cash € 75,544 € 103,944 € 19,124 € 19,124
Retained profit € 14,137 € 17,139 € 16,624 € 16,624
Balance sheet total € 75,544 € 104,760 € 19,124 € 19,124

Key figures of CESI-PREMED, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 4 December 2027.

What happened to CESI-PREMED?

What happened at CESI-PREMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2026: profit of € 0. Source: NBB ↗
  • Start of the company according to the CBE. KBO

In short

From € 2,986 profit in 2023 to € 0 profit in 2026.

Best year ever: 2024, with € 3,002 profit.

Establishments

Establishment units

Physical locations of this company

Registered office

Tiensevest 61 box 2

3010 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0887.903.059
VAT number
BE 0887.903.059
Registered office
Tiensevest 61 bus 2, 3010 Leuven
Names & denominations
CESI-PREMED
Enterprise type
Rechtspersoon
Legal form
General partnership
Legal situation
Normale toestand
Start date
13 March 2007
Peppol
Not registered

Frequently asked questions

What is the address of CESI-PREMED?
The registered office of CESI-PREMED is located at Tiensevest 61 box 2, 3010 Leuven.
Is CESI-PREMED still active?
Yes. According to the CBE (19 September 2026) CESI-PREMED is active, legal situation “Normale toestand”, started on 13 March 2007.
Is CESI-PREMED registered on Peppol?
No, CESI-PREMED is currently not registered on the Peppol network.
What is the enterprise number of CESI-PREMED?
The enterprise number of CESI-PREMED is BE0887903059.
When was CESI-PREMED founded?
CESI-PREMED was founded on 13 March 2007.
Is CESI-PREMED a reliable company?
Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 March 2007; 6 annual accounts filed, latest fiscal year 2026.